119 related articles for article (PubMed ID: 15389789)
1. Synergistic antiproliferative and apoptotic effects induced by mixed epidermal growth factor receptor inhibitor ZD1839 and nitric oxide donor in human prostatic cancer cell lines.
Mimeault M; Jouy N; Depreux P; Hénichart JP
Prostate; 2005 Feb; 62(2):187-99. PubMed ID: 15389789
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antiproliferative and apoptotic effects induced by epidermal growth factor receptor and protein kinase a inhibitors in human prostatic cancer cell lines.
Mimeault M; Pommery N; Hénichart JP
Int J Cancer; 2003 Aug; 106(1):116-24. PubMed ID: 12794766
[TBL] [Abstract][Full Text] [Related]
3. Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.
Sgambato A; Camerini A; Faraglia B; Ardito R; Bianchino G; Spada D; Boninsegna A; Valentini V; Cittadini A
J Cell Physiol; 2004 Oct; 201(1):97-105. PubMed ID: 15281092
[TBL] [Abstract][Full Text] [Related]
4. Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.
Mimeault M; Venkatraman G; Johansson SL; Moore E; Henichart JP; Depreux P; Lin MF; Batra SK
Int J Cancer; 2007 Jan; 120(1):160-9. PubMed ID: 17013895
[TBL] [Abstract][Full Text] [Related]
5. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production.
Mimeault M; Pommery N; Wattez N; Bailly C; Hénichart JP
Prostate; 2003 Jun; 56(1):1-12. PubMed ID: 12746841
[TBL] [Abstract][Full Text] [Related]
6. Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades.
Mimeault M; Mehta PP; Hauke R; Henichart JP; Depreux P; Lin MF; Batra SK
Growth Factors; 2007 Dec; 25(6):400-16. PubMed ID: 18365871
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells.
Mimeault M; Moore E; Moniaux N; Hénichart JP; Depreux P; Lin MF; Batra SK
Int J Cancer; 2006 Feb; 118(4):1022-31. PubMed ID: 16108016
[TBL] [Abstract][Full Text] [Related]
8. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth.
Premkumar DR; Arnold B; Pollack IF
Mol Carcinog; 2006 May; 45(5):288-301. PubMed ID: 16550610
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells.
Pu YS; Hsieh MW; Wang CW; Liu GY; Huang CY; Lin CC; Guan JY; Lin SR; Hour TC
Biochem Pharmacol; 2006 Mar; 71(6):751-60. PubMed ID: 16413505
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
[TBL] [Abstract][Full Text] [Related]
11. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
[TBL] [Abstract][Full Text] [Related]
12. ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma.
Teraishi F; Kagawa S; Watanabe T; Tango Y; Kawashima T; Umeoka T; Nisizaki M; Tanaka N; Fujiwara T
FEBS Lett; 2005 Aug; 579(19):4069-75. PubMed ID: 16023108
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
14. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.
Tortora G; Caputo R; Damiano V; Caputo R; Troiani T; Veneziani BM; De Placido S; Bianco AR; Zangemeister-Wittke U; Ciardiello F
Clin Cancer Res; 2003 Feb; 9(2):866-71. PubMed ID: 12576461
[TBL] [Abstract][Full Text] [Related]
15. Apigenin drives the production of reactive oxygen species and initiates a mitochondrial mediated cell death pathway in prostate epithelial cells.
Morrissey C; O'Neill A; Spengler B; Christoffel V; Fitzpatrick JM; Watson RW
Prostate; 2005 May; 63(2):131-42. PubMed ID: 15486995
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of ZD1839 alone or in combination with oxaliplatin in a panel of human tumor cell lines -- implications for clinical use.
Voigt W; Pickan V; Pfeiffer C; Mueller T; Simon H; Arnold D
Onkologie; 2005 Oct; 28(10):482-8. PubMed ID: 16160394
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells.
Matheny KE; Barbieri CE; Sniezek JC; Arteaga CL; Pietenpol JA
Laryngoscope; 2003 Jun; 113(6):936-9. PubMed ID: 12782800
[TBL] [Abstract][Full Text] [Related]
18. Modulation of survival signaling pathways and persistence of the genotoxic stress as a basis for the synergistic interaction between the atypical retinoid ST1926 and the epidermal growth factor receptor inhibitor ZD1839.
Zanchi C; Zuco V; Lanzi C; Supino R; Zunino F
Cancer Res; 2005 Mar; 65(6):2364-72. PubMed ID: 15781651
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures.
Vicentini C; Festuccia C; Gravina GL; Angelucci A; Marronaro A; Bologna M
J Cancer Res Clin Oncol; 2003 Mar; 129(3):165-74. PubMed ID: 12712332
[TBL] [Abstract][Full Text] [Related]
20. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.
Di Gennaro E; Barbarino M; Bruzzese F; De Lorenzo S; Caraglia M; Abbruzzese A; Avallone A; Comella P; Caponigro F; Pepe S; Budillon A
J Cell Physiol; 2003 Apr; 195(1):139-50. PubMed ID: 12599217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]